scholarly journals A SAS macro for a clustered logrank test

2011 ◽  
Vol 104 (2) ◽  
pp. 266-270 ◽  
Author(s):  
Margaret R. Stedman ◽  
David R. Gagnon ◽  
Robert A. Lew ◽  
Sin-Ho Jung ◽  
Elena Losina ◽  
...  
Keyword(s):  
Logrank Test ◽  
Sas Macro

The role of microRNAs in gliomas – Therapeutic implications

2020 ◽  
Vol 13 ◽  
Author(s):  
Theodora Katsila ◽  
Dimitrios Kardamakis
Keyword(s):  
Complex Disease ◽  
Malignant Gliomas ◽  
Kappa Statistic ◽  
Individual Variability ◽  
Response To Treatment ◽  
Disease Phenotype ◽  
Therapeutic Implications ◽  
Non Invasive ◽  
Gene Environment ◽  
Sas Macro

Background: Malignant gliomas constitute a complex disease phenotype that demands optimum decisionmaking. Despite being the most common type of primary brain tumors, gliomas are highly heterogeneous when their pathophysiology and response to treatment are considered. Such inter-individual variability also renders differential and early diagnosis extremely difficult. Recent evidence highlight that the gene-environment interplay becomes of fundamental importance in oncogenesis and progression of gliomas. Objective: To unmask key features of the gliomas disease phenotype and map the inter-individual variability of patients, we explore genotype-to-phenotype associations. Emphasis is put on microRNAs as they regulate gene expression, have been implicated in the pathogenesis of gliomas and may serve as theranostics, empowering non-invasive strategies (circulating free or in exosomes). Method: We mined text and omic datasets (as of 2019) and conducted a mixed-method content analysis. A novel framework was developed to meet the aims of our analysis, interrogating data in terms of content and context. We relied on literature data from PubMed/Medline and Scopus, as they are considered the largest abstract and citation databases of peer-reviewed literature. To avoid selection biases, both publicly available and private texts have been assessed. Both percent agreement and Cohen's kappa statistic have been calculated to avoid biases by SAS macro MAGREE with multicategorical ratings. Results: Gliomas serve as a paradigm for multifaceted datasets, despite data sparsity and scarcity. miRNAs and miRNAbased therapeutics are ready for prime time. Exosomal miRNAs empower non-invasive strategies, surpassing circulating free miRNAs, when accuracy and precision are considered. Conclusion: miRNAs holds promise as theranostics.

scholarly journals Factors Affecting the Control of Chronic Rhinosinusitis With Nasal Polyps: A Comparison in Patients With or Without NERD

2021 ◽  
Vol 12 ◽  
pp. 215265672110038
Author(s):  
Markus Jukka Lilja ◽  
Anni Koskinen ◽  
Paula Virkkula ◽  
Seija Inkeri Vento ◽  
Jyri Myller ◽  
...  
Keyword(s):  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Female Gender ◽  
Sinus Surgery ◽  
Logrank Test ◽  
Free Survival ◽  
Factors Affecting ◽  
Advanced Therapy ◽  
And Gender

Objectives The aim was to compare the control of chronic rhinosinusitis with nasal polyps (CRSwNP) after endoscopic sinus surgery (ESS), in patients with/without nonsteroidal anti-inflammatory drug exacerbated respiratory disease (NERD). Study Desing: A retrospective hospital-based sample of CRSwNP patients with/without NERD with follow-up. Setting Tertiary rhinology centers. Methods Electronic patient record data from 116 CRSwNP patients (46 with NERD and 70 without NERD) undergoing ESS during 2001–17 were studied. Mean follow-up time was 9.9 years (range 1.1–15.3). Endpoints reflecting uncontrolled CRSwNP were revision ESS, and need for rescue/advanced therapy (e.g. antibiotics, oral corticosteroids and/or biological therapy) during follow-up. NERD was variable of interest and gender, age, asthma, allergic rhinitis (AR), smoking, Lund-Mackay (LM) score of sinus computed tomography scans previous ESS and baseline total ethmoidectomy were used as covariates. Results Twenty-one (49.7%) NERD patients and 18 (25.7%) non-NERD patients underwent revision ESS within a mean ± SD of 4.3 ± 2.8 and 3.7 ± 2.6 years, respectively (p = .013, by Logrank test). In Cox´s regression models, NERD, female gender, young age, asthma, AR, previous ESS, and lack of total ethmoidectomy were associated with revision-ESS. In adjusted model, only the total ethmoidectomy predicted revision-free survival. In adjusted logistic regression model, there was an insignificant trend that NERD and LM score were associated with the need for rescue/advanced therapy in the follow-up. Conclusions Patients with NERD had higher risk of uncontrolled CRSwNP than patient group without NERD, as measured by revision ESS and/or need for rescue/advanced therapy in the follow-up. In addition, baseline total ethmoidectomy was associated with revision-free survival.

A SAS macro for the analysis of cell survival curves

2002 ◽  
Vol 67 (3) ◽  
pp. 201-207
Author(s):  
Mohammad A Chaudhary ◽  
Mohammad A Hannan
Keyword(s):  
Cell Survival ◽  
Survival Curves ◽  
Sas Macro

scholarly journals A global logrank test for adaptive treatment strategies based on observational studies

2013 ◽  
Vol 33 (5) ◽  
pp. 760-771 ◽  
Author(s):  
Zhiguo Li ◽  
Marcia Valenstein ◽  
Paul Pfeiffer ◽  
Dara Ganoczy
Keyword(s):  
Observational Studies ◽  
Treatment Strategies ◽  
Logrank Test ◽  
Adaptive Treatment ◽  
Adaptive Treatment Strategies

Abstract W P113: Prolonged Use of Clopidogrel and Aspirin and Stroke Risk in Intracranial Stenosis in SAMMPRIS

Stroke ◽  
2015 ◽  
Vol 46 (suppl_1) ◽  
Author(s):  
Christine Holmstedt ◽  
Michael J Lynn ◽  
Tanya N Turan ◽  
Colin P Derdeyn ◽  
David Fiorella ◽  
...  
Keyword(s):  
Primary Endpoint ◽  
Statistical Power ◽  
Intracranial Stenosis ◽  
Antithrombotic Agent ◽  
Logrank Test ◽  
Major Hemorrhage ◽  
Exact Test ◽  
Lipid Disorder ◽  
Primary Endpoints ◽  
Event Rates

Background: In the SAMMPRIS trial, the use of combination aspirin and clopidogrel for 90 days after enrollment could be one reason that the outcome of patients in the medical arm was better than expected. The SAMMPRIS protocol required stopping clopidogrel after 90 days unless the patient had a non-neurological indication for continued use. We sought to compare outcomes in patients on vs. off clopidogrel beyond 90 days. Methods: For patients who did not have a primary endpoint within 90 days after enrollment (n = 397), we compared baseline features (t and Fisher’s exact tests), survival curves for the primary endpoint beyond 90 days after enrollment (the logrank test), and major hemorrhages (Fisher’s exact test) in patients on vs. off clopidogrel in the medical arm and stenting arms. Results: In the medical and stenting groups combined, baseline factors that were significantly (p<0.05) different between those on vs. off clopidogrel beyond 90 days (all higher in on clopidogrel group) were: age, diabetes, lipid disorder, coronary disease, SBP, and on antithrombotic agent at qualifying event. The table shows the primary endpoints and major hemorrhages in patients on vs. off clopidogrel in both treatment groups. Conclusion: This analysis, which was underpowered to detect even very large differences in event rates, suggests that prolonged use of clopidogrel plus aspirin may lower the risk of stroke in medically treated patients with intracranial stenosis, but increase the risk of major hemorrhage. Further studies with higher statistical power are needed to test this hypothesis.

Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer

2006 ◽  
Vol 24 (13) ◽  
pp. 1982-1989 ◽  
Author(s):  
Norihiko Tsuchiya ◽  
Lizhong Wang ◽  
Hiroyoshi Suzuki ◽  
Takehiko Segawa ◽  
Hisami Fukuda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Cancer Patients ◽  
Genetic Polymorphisms ◽  
Metastatic Prostate Cancer ◽  
Genetic Factors ◽  
Response To Treatment ◽  
Logrank Test ◽  
Ca Repeat ◽  
Igf I

Purpose The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. Patients and Methods One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. Results Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). Conclusion The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.

Comparison of Survivorship by the Logrank Test: Criticisms and Alternatives

Ecology ◽  
1991 ◽  
Vol 72 (6) ◽  
pp. 2290-2293 ◽  
Author(s):  
Michael J. Hutchings ◽  
Karen D. Booth ◽  
Stephen Waite
Keyword(s):  
Logrank Test
Sign in / Sign up

Export Citation Format

Share Document